Seeds, like just about every other aspect of the ag industry, have been undergoing technological advances designed to deliver greater yields and better return on investment. And while much of the focus for ag technology has focused on addressing issues outside of the plant, BioLumic, a New Zealand-based company, is working to flip that focus to the inside of the plant. Read more...
Read MoreSAN JOSE, Calif.–(BUSINESS WIRE)–Stellar Cyber Chief Revenue Officer Jim O’Hara and VP of Strategic Alliances Andrew Homer both have been named to the prestigious 2025 CRN® Channel Chiefs list. CRN produces the Channel Chiefs list to showcase the top leaders throughout the IT channel ecosystem who work tirelessly with their partners and customers to ensure mutual success. The list recognizes IT vendor and distribution executives who drive strategy and set the channel agenda for their companies and the industry. Read more...
Read MoreDuring the more extreme seasons. we tend to value the importance of having heating or cooling in our homes. With that comes an unspoken trust between us and the systems we rely on to keep us comfortable. Listen...
Read MoreNEW YORK, NY, UNITED STATES, February 3, 2025 — DailyPay, a worktech company and leading provider of earned wage access and goHappy, the leader in frontline employee engagement solutions, announced a new strategic partnership designed to simplify frontline workers’ access to their earned wages. Read...
Read MoreJERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients. Read...
Read More
